Cyclic Ruthenium-Peptide Prodrugs Penetrate the Blood–Brain Barrier and Attack Glioblastoma upon Light Activation in Orthotopic Zebrafish Tumor Models
Open Access
- 9 December 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 10 (12) , 2294-2311
Abstract
The blood-brain barrier (BBB) presents one of the main obstacles to delivering anticancer drugs in glioblastoma. Herein, we investigated the potential of a series of cyclic ruthenium-peptide conjugates as photoactivated therapy candidates for the treatment of this aggressive tumor. The three compounds studied, Ru-p(HH), Ru-p(MH), and Ru-p(MM) ([Ru(Ph2phen)2 (Ac-X1RGDX2-NH2)]Cl2 with Ph2phen = 4,7-diphenyl-1,10-phenanthroline and X1, X2 = His or Met), include an integrin-targeted pentapeptide coordinated to a ruthenium warhead via two photoactivated ruthenium-X1,2 bonds. Their photochemistry, activation mechanism, tumor targeting, and antitumor activity were meticulously addressed. A combined in vitro and in vivo study revealed that the photoactivated cell-killing mechanism and their O2 dependence were strongly influenced by the nature of X1 and X2. Ru-p(MM) was shown to be a photoactivated chemotherapy (PACT) drug, while Ru-p(HH) behaved as a photodynamic therapy (PDT) drug. All conjugates, however, showed comparable antitumor targeting and efficacy toward human glioblastoma 3D spheroids and orthotopic glioblastoma tumor models in zebrafish embryos. Most importantly, in this model, all three compounds could effectively cross the BBB, resulting in excellent targeting of the tumors in the brain.Keywords
Funding Information
- China Scholarship Council (201806450039, 201906340159)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
This publication has 62 references indexed in Scilit:
- Red‐Light Activation of a Microtubule Polymerization Inhibitor via Amide Functionalization of the Ruthenium PhotocageAngewandte Chemie International Edition, 2023
- The blood-brain barrier: Physiology and strategies for drug deliveryAdvanced Drug Delivery Reviews, 2020
- Zebrafish as a preclinical in vivo screening model for nanomedicinesAdvanced Drug Delivery Reviews, 2019
- New Designs for Phototherapeutic Transition Metal ComplexesAngewandte Chemie International Edition, 2019
- A Red‐Light‐Activated Ruthenium‐Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer CellsAngewandte Chemie, 2017
- RETRACTED: Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A reviewBiomedicine & Pharmacotherapy, 2017
- A brief report on the history of phototherapyClinics in Dermatology, 2016
- Identification of the Structural Determinants for Anticancer Activity of a Ruthenium Arene Peptide ConjugateChemistry – A European Journal, 2013
- Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment deliveryJournal of Neuro-Oncology, 2011
- Chemistry with ADFJournal of Computational Chemistry, 2001